STOCK TITAN

Fuller & Thaler discloses 5.10% Indivior (INDV) stake on Schedule 13G

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. disclosed that Fuller & Thaler Asset Management, Inc., a California-based investment adviser, beneficially owns 6,371,533.70 shares of its common stock, representing 5.10% of the class as of 12/31/2025.

Fuller & Thaler reports sole voting power over 6,193,613.70 shares and sole dispositive power over 6,371,533.70 shares, with no shared voting or dispositive power. The firm states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Indivior.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Fuller & Thaler Asset Management, Inc.
Signature:/s/ Hanna Zanoni
Name/Title:Chief Compliance Officer
Date:02/17/2026

FAQ

What stake does Fuller & Thaler hold in Indivior Pharmaceuticals (INDV)?

Fuller & Thaler Asset Management, Inc. reports beneficial ownership of 6,371,533.70 Indivior common shares, equal to 5.10% of the class. This reflects a significant institutional position above the 5% reporting threshold for Schedule 13G filings.

What voting power does Fuller & Thaler report over INDV shares?

Fuller & Thaler reports sole voting power over 6,193,613.70 shares of Indivior common stock and no shared voting power. This indicates the firm can vote or direct the vote for that number of shares under its discretionary authority.

What dispositive power does Fuller & Thaler have over Indivior (INDV) stock?

Fuller & Thaler reports sole dispositive power over 6,371,533.70 shares of Indivior common stock and no shared dispositive power. Dispositive power means the firm can decide whether and when to sell those shares for its advisory clients.

Why is Fuller & Thaler deemed the beneficial owner of INDV shares?

Fuller & Thaler is deemed beneficial owner because it acts as investment adviser for various clients holding Indivior shares. Under separate advisory arrangements, it directs investment decisions, while each underlying client retains the economic interest in dividends and sale proceeds.

Is Fuller & Thaler seeking to influence control of Indivior Pharmaceuticals?

Fuller & Thaler certifies the Indivior shares were acquired and are held in the ordinary course of business and not for changing or influencing control. The position is reported on Schedule 13G, typically used for passive or non‑control-oriented holdings.

What triggered this Indivior (INDV) Schedule 13G filing date?

The filing relates to a 12/31/2025 event date, when Fuller & Thaler’s beneficial ownership in Indivior common stock reached or exceeded 5%. Crossing that threshold requires a Schedule 13G or 13D to disclose the institutional holder’s stake and control intentions.
Indivior Pharmaceuticals Inc

NASDAQ:INDV

INDV Rankings

INDV Latest News

INDV Latest SEC Filings

INDV Stock Data

4.34B
120.19M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SLOUGH, BERKSHIRE